These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23357198)

  • 1. Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans.
    Peters W; Brandl JR; Lindbloom JD; Martinez CJ; Scallan CD; Trager GR; Tingley DW; Kabongo ML; Tucker SN
    Vaccine; 2013 Mar; 31(13):1752-8. PubMed ID: 23357198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral immunization with recombinant Lactococcus lactis expressing the hemagglutinin of the avian influenza virus induces mucosal and systemic immune responses.
    Wang Z; Gao J; Yu Q; Yang Q
    Future Microbiol; 2012 Aug; 7(8):1003-10. PubMed ID: 22913358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity of recombinant adenovirus-vectored vaccines expressing different forms of hemagglutinin (HA) proteins from the H5 serotype of influenza A viruses in mice.
    Hu X; Meng W; Dong Z; Pan W; Sun C; Chen L
    Virus Res; 2011 Jan; 155(1):156-62. PubMed ID: 20883733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
    Prabakaran M; Kolpe AB; He F; Kwang J
    Vaccine; 2013 Feb; 31(10):1385-92. PubMed ID: 23328313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
    Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
    Ledgerwood JE; Hu Z; Gordon IJ; Yamshchikov G; Enama ME; Plummer S; Bailer R; Pearce MB; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1792-7. PubMed ID: 22956656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.
    Treanor JJ; Essink B; Hull S; Reed S; Izikson R; Patriarca P; Goldenthal KL; Kohberger R; Dunkle LM
    Vaccine; 2013 Nov; 31(48):5760-5. PubMed ID: 24075920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge.
    Kheiri MT; Jamali A; Shenagari M; Hashemi H; Sabahi F; Atyabi F; Saghiri R
    Antiviral Res; 2012 Sep; 95(3):229-36. PubMed ID: 22809863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.
    Francis JN; Bunce CJ; Horlock C; Watson JM; Warrington SJ; Georges B; Brown CB
    Vaccine; 2015 Jan; 33(2):396-402. PubMed ID: 24928790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved immune responses against avian influenza virus following oral vaccination of chickens with HA DNA vaccine using attenuated Salmonella typhimurium as carrier.
    Jazayeri SD; Ideris A; Zakaria Z; Yeap SK; Omar AR
    Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):417-27. PubMed ID: 22512819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baculovirus vector as an avian influenza vaccine: hemagglutinin expression and presentation augment the vaccine immunogenicity.
    Chen CY; Lin SY; Cheng MC; Tsai CP; Hung CL; Lo KW; Hwang Y; Hu YC
    J Biotechnol; 2013 Mar; 164(1):143-50. PubMed ID: 23313887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs.
    Xu J; Huang D; Liu S; Lin H; Zhu H; Liu B; Lu C
    Virus Res; 2012 Aug; 167(2):188-95. PubMed ID: 22584406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Cooper CL; Davis HL; Morris ML; Efler SM; Krieg AM; Li Y; Laframboise C; Al Adhami MJ; Khaliq Y; Seguin I; Cameron DW
    Vaccine; 2004 Aug; 22(23-24):3136-43. PubMed ID: 15297066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.
    Gao W; Soloff AC; Lu X; Montecalvo A; Nguyen DC; Matsuoka Y; Robbins PD; Swayne DE; Donis RO; Katz JM; Barratt-Boyes SM; Gambotto A
    J Virol; 2006 Feb; 80(4):1959-64. PubMed ID: 16439551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
    Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
    Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients.
    Avetisyan G; Ragnavölgyi E; Toth GT; Hassan M; Ljungman P
    Bone Marrow Transplant; 2005 Sep; 36(5):411-5. PubMed ID: 15980884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.